PRIORITIZE Abstract-Manuscripts 2022 Release

TITLE Journal/Meeting Decision Authors DOI
Oral direct-acting agent therapy for Hepatitis C:  A Systematic Review Annals of Internal Medicine Accepted Feb2017 Oluwseun Falade-Nwulia MBBS, MPH,1*; Catalina Suarez-Cuervo MD2*, David R. Nelson MD3, Michael W. Fried MD4, Jodi B. Segal MD, MPH2, and Mark S. Sulkowski MD1 DOI: 10.7326/M16-2575
THE PRIORITIZE STUDY:  A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders EASL2019 Accepted POSTER Sulkowski, MS; Moon, J; Sherman, K; Darling, J; Muir, A; Khalili, M; Fishbein, D; Hinestrosa, F; Shiffman, ML; Di Bisceglie, AM; Reddy, RK; Pearlman, B; Lok, AS; Fried, MW; Stewart, P; Peter, J; Wadsworth, S; Vainorius, M; Michael, L; Evon, D, Segal, J; and Nelson DR on behalf of the PRIORITIZE study team
Experiences of an HCV Patient Engagement Group: A Seven-Year Journey Research Involvement and Engagement Accepted 11.6.2020 Kixmiller, Brown, Chaney, Franciscus, Huston, Thomas, and Wadsworth DOI: 10.1186/s40900-021-00249-2
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study Hepatology Accepted Hepatology Epub 2021 Aug 26 Sulkowski, Moon, Sherman, Morelli, Darling,  Muir,  Khalili, Fishbein, Hinestrosa,  Shiffman, Di Bisceglie,  Reddy, Pearlman,  Lok, Fried, Stewart, Peter, Wadsworth, Kixmiller, Sloan, Vainorius, Horne,  Michael,  Dong,  Evon, Segal, Nelson D DOI: 10.1002/hep.32053
Formulary Restrictions May Impact Enrollment in Pragmatic Trials and Limit Generalizability of Findings to Vulnerable Populations Clinical Trials Accepted 5.4.2020 Jodi B. Segal DOI: 10.1177/1740774520941257
Long-term follow-up of hepatitis C patients who achieved sustained virologic response in the pragmatic PRIORITIZE Study Clinical Gastroenterology and Hepatology Accepted  1.26.2022 (CGH-D-21-02843R1) Anna S Lok; Juhi Moon; Kenneth E Sherman; Mandana Khalili; Dawn Fishbein; K. Rajender Reddy; on behalf of the PRIORITIZE Study Team pending